Cardiotoxicity  ||| S:0 E:15 ||| RB
associated  ||| S:15 E:26 ||| VBN
with  ||| S:26 E:31 ||| IN
trastuzumab  ||| S:31 E:43 ||| JJ
treatment  ||| S:43 E:53 ||| NN
of  ||| S:53 E:56 ||| IN
HER2+  ||| S:56 E:62 ||| CD
breast  ||| S:62 E:69 ||| NN
cancer  ||| S:69 E:76 ||| NN
Although  ||| S:76 E:85 ||| IN
having  ||| S:85 E:92 ||| VBG
high  ||| S:92 E:97 ||| JJ
clinical  ||| S:97 E:106 ||| JJ
efficacy  ||| S:106 E:115 ||| NN
in  ||| S:115 E:118 ||| IN
the  ||| S:118 E:122 ||| DT
treatment  ||| S:122 E:132 ||| NN
of  ||| S:132 E:135 ||| IN
human  ||| S:135 E:141 ||| JJ
epidermal  ||| S:141 E:151 ||| JJ
growth  ||| S:151 E:158 ||| NN
factor  ||| S:158 E:165 ||| NN
receptor-2  ||| S:165 E:176 ||| NNP
( ||| S:176 E:177 ||| -LRB-
HER2+ ||| S:177 E:182 ||| NNP
)  ||| S:182 E:184 ||| -RRB-
metastatic  ||| S:184 E:195 ||| JJ
breast  ||| S:195 E:202 ||| NN
cancer ||| S:202 E:208 ||| NN
,  ||| S:208 E:210 ||| ,
trastuzumab  ||| S:210 E:222 ||| NN
has  ||| S:222 E:226 ||| VBZ
been  ||| S:226 E:231 ||| VBN
associated  ||| S:231 E:242 ||| VBN
with  ||| S:242 E:247 ||| IN
cardiotoxicity ||| S:247 E:261 ||| NN
,  ||| S:261 E:263 ||| ,
and  ||| S:263 E:267 ||| CC
the  ||| S:267 E:271 ||| DT
etiology  ||| S:271 E:280 ||| NN
and  ||| S:280 E:284 ||| CC
pathogenesis  ||| S:284 E:297 ||| NN
of  ||| S:297 E:300 ||| IN
this  ||| S:300 E:305 ||| DT
condition  ||| S:305 E:315 ||| NN
is  ||| S:315 E:318 ||| VBZ
currently  ||| S:318 E:328 ||| RB
under  ||| S:328 E:334 ||| IN
investigation ||| S:334 E:347 ||| NN
.  ||| S:347 E:349 ||| .
This  ||| S:349 E:354 ||| DT
paper  ||| S:354 E:360 ||| NN
reviews  ||| S:360 E:368 ||| VBZ
the  ||| S:368 E:372 ||| DT
cardiotoxicity ||| S:372 E:386 ||| NN
,  ||| S:386 E:388 ||| ,
associated  ||| S:388 E:399 ||| VBN
with  ||| S:399 E:404 ||| IN
trastuzumab  ||| S:404 E:416 ||| JJ
use  ||| S:416 E:420 ||| NN
and  ||| S:420 E:424 ||| CC
discusses  ||| S:424 E:434 ||| VBG
the  ||| S:434 E:438 ||| DT
risk  ||| S:438 E:443 ||| NN
assessment  ||| S:443 E:454 ||| NN
and  ||| S:454 E:458 ||| CC
management  ||| S:458 E:469 ||| NN
of  ||| S:469 E:472 ||| IN
cardiac  ||| S:472 E:480 ||| JJ
dysfunction ||| S:480 E:491 ||| NN
.  ||| S:491 E:493 ||| .
The  ||| S:493 E:497 ||| DT
increased  ||| S:497 E:507 ||| JJ
risk  ||| S:507 E:512 ||| NN
of  ||| S:512 E:515 ||| IN
cardiotoxicity  ||| S:515 E:530 ||| NN
is  ||| S:530 E:533 ||| VBZ
lower  ||| S:533 E:539 ||| JJR
when  ||| S:539 E:544 ||| WRB
trastuzumab  ||| S:544 E:556 ||| NN
is  ||| S:556 E:559 ||| VBZ
given  ||| S:559 E:565 ||| VBN
as  ||| S:565 E:568 ||| IN
monotherapy  ||| S:568 E:580 ||| NNS
( ||| S:580 E:581 ||| -LRB-
3 ||| S:581 E:582 ||| CD
% ||| S:582 E:583 ||| NN
-7 ||| S:583 E:585 ||| CD
% ||| S:585 E:586 ||| NN
)  ||| S:586 E:588 ||| -RRB-
compared  ||| S:588 E:597 ||| VBN
with  ||| S:597 E:602 ||| IN
anthracyclines  ||| S:602 E:617 ||| FW
+  ||| S:617 E:619 ||| FW
trastuzumab  ||| S:619 E:631 ||| FW
therapy  ||| S:631 E:639 ||| FW
( ||| S:639 E:640 ||| -LRB-
27 ||| S:640 E:642 ||| CD
% ||| S:642 E:643 ||| NN
) ||| S:643 E:644 ||| -RRB-
.  ||| S:644 E:646 ||| .
Type  ||| S:646 E:651 ||| NNP
II  ||| S:651 E:654 ||| NNP
cardiac  ||| S:654 E:662 ||| JJ
changes  ||| S:662 E:670 ||| NNS
occur  ||| S:670 E:676 ||| VBP
in  ||| S:676 E:679 ||| IN
trastuzumab-treated  ||| S:679 E:699 ||| JJ
patients ||| S:699 E:707 ||| NNS
,  ||| S:707 E:709 ||| ,
which  ||| S:709 E:715 ||| WDT
do  ||| S:715 E:718 ||| VBP
not  ||| S:718 E:722 ||| RB
appear  ||| S:722 E:729 ||| VB
to  ||| S:729 E:732 ||| TO
be  ||| S:732 E:735 ||| VB
dose-related ||| S:735 E:747 ||| JJ
,  ||| S:747 E:749 ||| ,
are  ||| S:749 E:753 ||| VBP
not  ||| S:753 E:757 ||| RB
associated  ||| S:757 E:768 ||| VBN
with  ||| S:768 E:773 ||| IN
histological  ||| S:773 E:786 ||| JJ
changes ||| S:786 E:793 ||| NNS
,  ||| S:793 E:795 ||| ,
and  ||| S:795 E:799 ||| CC
are  ||| S:799 E:803 ||| VBP
generally  ||| S:803 E:813 ||| RB
reversible ||| S:813 E:823 ||| JJ
.  ||| S:823 E:825 ||| .
Several  ||| S:825 E:833 ||| JJ
risk  ||| S:833 E:838 ||| NN
factors  ||| S:838 E:846 ||| NNS
for  ||| S:846 E:850 ||| IN
cardiac  ||| S:850 E:858 ||| JJ
events  ||| S:858 E:865 ||| NNS
have  ||| S:865 E:870 ||| VBP
been  ||| S:870 E:875 ||| VBN
identified  ||| S:875 E:886 ||| VBN
and  ||| S:886 E:890 ||| CC
assessing  ||| S:890 E:900 ||| VBG
levels  ||| S:900 E:907 ||| NNS
of  ||| S:907 E:910 ||| IN
troponin  ||| S:910 E:919 ||| VBG
I  ||| S:919 E:921 ||| PRP
and  ||| S:921 E:925 ||| CC
N-terminal  ||| S:925 E:936 ||| JJ
pro-brain  ||| S:936 E:946 ||| JJ
B-type  ||| S:946 E:953 ||| JJ
natriuretic  ||| S:953 E:965 ||| JJ
peptide  ||| S:965 E:973 ||| NN
before  ||| S:973 E:980 ||| IN
and  ||| S:980 E:984 ||| CC
after  ||| S:984 E:990 ||| IN
treatment  ||| S:990 E:1000 ||| NN
with  ||| S:1000 E:1005 ||| IN
trastuzumab  ||| S:1005 E:1017 ||| NNS
may  ||| S:1017 E:1021 ||| MD
allow  ||| S:1021 E:1027 ||| VB
early  ||| S:1027 E:1033 ||| JJ
detection  ||| S:1033 E:1043 ||| NN
of  ||| S:1043 E:1046 ||| IN
cardiotoxicity ||| S:1046 E:1060 ||| NN
.  ||| S:1060 E:1062 ||| .
A  ||| S:1062 E:1064 ||| DT
symptomatic  ||| S:1064 E:1076 ||| NN
and  ||| S:1076 E:1080 ||| CC
functional  ||| S:1080 E:1091 ||| JJ
evaluation  ||| S:1091 E:1102 ||| NN
scheme  ||| S:1102 E:1109 ||| NN
for  ||| S:1109 E:1113 ||| IN
patients  ||| S:1113 E:1122 ||| NNS
indicated  ||| S:1122 E:1132 ||| VBD
for  ||| S:1132 E:1136 ||| IN
treatment  ||| S:1136 E:1146 ||| NN
with  ||| S:1146 E:1151 ||| IN
trastuzumab  ||| S:1151 E:1163 ||| NN
has  ||| S:1163 E:1167 ||| VBZ
also  ||| S:1167 E:1172 ||| RB
been  ||| S:1172 E:1177 ||| VBN
proposed  ||| S:1177 E:1186 ||| VBN
to  ||| S:1186 E:1189 ||| TO
work  ||| S:1189 E:1194 ||| VB
alongside  ||| S:1194 E:1204 ||| IN
therapeutic  ||| S:1204 E:1216 ||| JJ
options  ||| S:1216 E:1224 ||| NNS
for  ||| S:1224 E:1228 ||| IN
the  ||| S:1228 E:1232 ||| DT
treatment  ||| S:1232 E:1242 ||| NN
of  ||| S:1242 E:1245 ||| IN
heart  ||| S:1245 E:1251 ||| NN
failure ||| S:1251 E:1258 ||| NN
.  ||| S:1258 E:1260 ||| .
The  ||| S:1260 E:1264 ||| DT
risk  ||| S:1264 E:1269 ||| NN
of  ||| S:1269 E:1272 ||| IN
cardiac  ||| S:1272 E:1280 ||| JJ
dysfunction  ||| S:1280 E:1292 ||| NNS
associated  ||| S:1292 E:1303 ||| VBN
with  ||| S:1303 E:1308 ||| IN
trastuzumab  ||| S:1308 E:1320 ||| NNS
can  ||| S:1320 E:1324 ||| MD
be  ||| S:1324 E:1327 ||| VB
justified  ||| S:1327 E:1337 ||| VBN
given  ||| S:1337 E:1343 ||| VBN
the  ||| S:1343 E:1347 ||| DT
increase  ||| S:1347 E:1356 ||| NN
in  ||| S:1356 E:1359 ||| IN
overall  ||| S:1359 E:1367 ||| JJ
survival ||| S:1367 E:1375 ||| NN
.  ||| S:1375 E:1377 ||| .
This  ||| S:1377 E:1382 ||| DT
risk  ||| S:1382 E:1387 ||| NN
is  ||| S:1387 E:1390 ||| VBZ
lower  ||| S:1390 E:1396 ||| JJR
when  ||| S:1396 E:1401 ||| WRB
trastuzumab  ||| S:1401 E:1413 ||| NN
is  ||| S:1413 E:1416 ||| VBZ
given  ||| S:1416 E:1422 ||| VBN
as  ||| S:1422 E:1425 ||| IN
monotherapy ||| S:1425 E:1436 ||| NN
.  ||| S:1436 E:1438 ||| .
The  ||| S:1438 E:1442 ||| DT
paradigm  ||| S:1442 E:1451 ||| NN
for  ||| S:1451 E:1455 ||| IN
cardiologists  ||| S:1455 E:1469 ||| NN
remains  ||| S:1469 E:1477 ||| VBZ
the  ||| S:1477 E:1481 ||| DT
same ||| S:1481 E:1485 ||| JJ
:  ||| S:1485 E:1487 ||| :
treat  ||| S:1487 E:1493 ||| VB
the  ||| S:1493 E:1497 ||| DT
cancer  ||| S:1497 E:1504 ||| NN
effectively  ||| S:1504 E:1516 ||| RB
whilst  ||| S:1516 E:1523 ||| VBP
preventing  ||| S:1523 E:1534 ||| VBG
cardiotoxicity ||| S:1534 E:1548 ||| NNS
.  ||| S:1548 E:1550 ||| .
